Cargando…
Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Signature for Ovarian Cancers
Ovarian cancer (OC), one of the most common malignancies of the female reproductive system, is characterized by high incidence and poor prognosis. Tumor mutation burden (TMB), as an important biomarker that can represent the degree of tumor mutation, is emerging as a key indicator for predicting the...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787320/ https://www.ncbi.nlm.nih.gov/pubmed/35087563 http://dx.doi.org/10.3389/fgene.2021.688207 |
_version_ | 1784639336329773056 |
---|---|
author | Cui, Mengjing Xia, Qianqian Zhang, Xing Yan, Wenjing Meng, Dan Xie, Shuqian Shen, Siyuan Jin, Hua Wang, Shizhi |
author_facet | Cui, Mengjing Xia, Qianqian Zhang, Xing Yan, Wenjing Meng, Dan Xie, Shuqian Shen, Siyuan Jin, Hua Wang, Shizhi |
author_sort | Cui, Mengjing |
collection | PubMed |
description | Ovarian cancer (OC), one of the most common malignancies of the female reproductive system, is characterized by high incidence and poor prognosis. Tumor mutation burden (TMB), as an important biomarker that can represent the degree of tumor mutation, is emerging as a key indicator for predicting the efficacy of tumor immunotherapy. In our study, the gene expression profiles of OC were downloaded from TCGA and GEO databases. Subsequently, we analyzed the prognostic value of TMB in OC and found that a higher TMB score was significantly associated with a better prognosis (p = 0.004). According to the median score of TMB, 9 key TMB related immune prognostic genes were selected by LASSO regression for constructing a TMB associated immune risk score (TMB-IRS) signature, which can effectively predict the prognosis of OC patients (HR = 2.32, 95% CI = 1.68–3.32; AUC = 0.754). Interestingly, TMB-IRS is also closely related to the level of immune cell infiltration and immune checkpoint molecules (PD1, PD-L1, CTLA4, PD-L2) in OC. Furthermore, the nomogram combined with TMB-IRS and a variety of clinicopathological features can more comprehensively evaluate the prognosis of patients. In conclusion, we explored the relationship between TMB and prognosis and validated the TMB-IRS signature based on TMB score in an independent database (HR = 1.60, 95% CI = 1.13–2.27; AUC = 0.639), which may serve as a novel biomarker for predicting OC prognosis as well as possible therapeutic targets. |
format | Online Article Text |
id | pubmed-8787320 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87873202022-01-26 Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Signature for Ovarian Cancers Cui, Mengjing Xia, Qianqian Zhang, Xing Yan, Wenjing Meng, Dan Xie, Shuqian Shen, Siyuan Jin, Hua Wang, Shizhi Front Genet Genetics Ovarian cancer (OC), one of the most common malignancies of the female reproductive system, is characterized by high incidence and poor prognosis. Tumor mutation burden (TMB), as an important biomarker that can represent the degree of tumor mutation, is emerging as a key indicator for predicting the efficacy of tumor immunotherapy. In our study, the gene expression profiles of OC were downloaded from TCGA and GEO databases. Subsequently, we analyzed the prognostic value of TMB in OC and found that a higher TMB score was significantly associated with a better prognosis (p = 0.004). According to the median score of TMB, 9 key TMB related immune prognostic genes were selected by LASSO regression for constructing a TMB associated immune risk score (TMB-IRS) signature, which can effectively predict the prognosis of OC patients (HR = 2.32, 95% CI = 1.68–3.32; AUC = 0.754). Interestingly, TMB-IRS is also closely related to the level of immune cell infiltration and immune checkpoint molecules (PD1, PD-L1, CTLA4, PD-L2) in OC. Furthermore, the nomogram combined with TMB-IRS and a variety of clinicopathological features can more comprehensively evaluate the prognosis of patients. In conclusion, we explored the relationship between TMB and prognosis and validated the TMB-IRS signature based on TMB score in an independent database (HR = 1.60, 95% CI = 1.13–2.27; AUC = 0.639), which may serve as a novel biomarker for predicting OC prognosis as well as possible therapeutic targets. Frontiers Media S.A. 2022-01-11 /pmc/articles/PMC8787320/ /pubmed/35087563 http://dx.doi.org/10.3389/fgene.2021.688207 Text en Copyright © 2022 Cui, Xia, Zhang, Yan, Meng, Xie, Shen, Jin and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Genetics Cui, Mengjing Xia, Qianqian Zhang, Xing Yan, Wenjing Meng, Dan Xie, Shuqian Shen, Siyuan Jin, Hua Wang, Shizhi Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Signature for Ovarian Cancers |
title | Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Signature for Ovarian Cancers |
title_full | Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Signature for Ovarian Cancers |
title_fullStr | Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Signature for Ovarian Cancers |
title_full_unstemmed | Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Signature for Ovarian Cancers |
title_short | Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Signature for Ovarian Cancers |
title_sort | development and validation of a tumor mutation burden-related immune prognostic signature for ovarian cancers |
topic | Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787320/ https://www.ncbi.nlm.nih.gov/pubmed/35087563 http://dx.doi.org/10.3389/fgene.2021.688207 |
work_keys_str_mv | AT cuimengjing developmentandvalidationofatumormutationburdenrelatedimmuneprognosticsignatureforovariancancers AT xiaqianqian developmentandvalidationofatumormutationburdenrelatedimmuneprognosticsignatureforovariancancers AT zhangxing developmentandvalidationofatumormutationburdenrelatedimmuneprognosticsignatureforovariancancers AT yanwenjing developmentandvalidationofatumormutationburdenrelatedimmuneprognosticsignatureforovariancancers AT mengdan developmentandvalidationofatumormutationburdenrelatedimmuneprognosticsignatureforovariancancers AT xieshuqian developmentandvalidationofatumormutationburdenrelatedimmuneprognosticsignatureforovariancancers AT shensiyuan developmentandvalidationofatumormutationburdenrelatedimmuneprognosticsignatureforovariancancers AT jinhua developmentandvalidationofatumormutationburdenrelatedimmuneprognosticsignatureforovariancancers AT wangshizhi developmentandvalidationofatumormutationburdenrelatedimmuneprognosticsignatureforovariancancers |